Herbert Irving Comprehensive Cancer Center
Benjamin Izar, MD
Benjamin Izar, MD, Ph.D. is an assistant professor of medicine at the Columbia Vagelos College of Physicians and Surgeons in the division of Hematology/Oncology and a member of the Tumor Biology and Microenvironment Program at the Herbert Irving Comprehensive Cancer Center. Dr. Izar’s clinical practice focuses on melanoma and cancer immunotherapy. In his lab, Dr. Izar studies interactions between cancer cells and cells of the tumor-microenvironment, and how these define metastatic niches, response, and resistance to cancer immunotherapies. His lab develops and uses cutting-edge single-cell genomics and genome-editing tools to study patient tumors and models at unprecedented resolution.

Dr. Izar received his MD/Ph.D. at Justus Liebig University in Giessen, Germany, where he graduated summa cum laude. He completed his internal medicine residency training at Massachusetts General Hospital and medical oncology training at Beth Israel Deaconess Medical Center, followed by his first faculty position at Danna-Farber Cancer Institute. He completed post-doctoral research training in cancer immunology at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

In addition to several awards he received during his training, Dr. Izar is the recipient of multiple national awards, including an NIH/NCI K08 Award (2017) and the prestigious Burroughs Welcome Fund Career Award for Medical Scientists (2018), and he was selected as a NextGen Star of the American Association for Cancer Research (2019). In 2020, he was selected as a Louis V. Gerstner, Jr. Scholar and a Velocity Fellow by Columbia University Vagelos College of Physicians and Surgeons. Dr. Izar is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the Society for Immunotherapy of Cancer, and the Society for Melanoma Research.

Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A study for patients with sarcoma using study drug MGCD516
Cancer [ CLOSED ] Study of COM701 Alone and in Combination with Nivolumain in Patients with Advanced Solid Tumors (Breast Cancer/Ovarian Cancer/Lung Cancer)
Cancer [ CLOSED ] A Study in Subjects With Advanced Cancer
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers
Melanoma [ CLOSED ] CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Cancer [ CLOSED ] COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors
Cancer [ CLOSED ] A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Cancer
Sarcoma [ CLOSED ] Study of ATX-101 in Patients with Dedifferentiated Liposarcoma (LPS) and Leiomyosarcoma (LMS)
Melanoma [ CLOSED ] Study of ALKS 4230 in Patients with Previously Treated Advanced Melanoma
Cancer Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors
Melanoma Study of Fianlimab and Cemiplimab vs. Pembrolizumab in Patients with Resected High-Risk Melanoma
Skin Cancer Study of IMC-F106C in Combination with Nivolumab in Patients with Advanced Melanoma
Melanoma Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma